
    
      Approximately 44 patients are to be randomized in a 3:1 ratio to two possible treatment
      groups, pardoprunox and pramipexole, respectively. The first part of the study will be
      blinded and consists of a minimum 1-week screening period, a 4-week switch and stabilization
      period and an 8-week maintenance period. The second part of the study will be open label
      pardoprunox treatment with a dose adjustment period of 4 weeks followed by long term
      maintenance treatment.
    
  